“Nirogy” means “without illness” in Sanskrit. Our vision is to create a path to end patient suffering. Nirogy has been trying to unravel the intricate symbiotic communication network among various cell types in the tumor and immune microenvironment (TIME)…
“Nirogy” means “without illness” in Sanskrit. Our vision is to create a path to end patient suffering. Nirogy has been trying to unravel the intricate symbiotic communication network among various cell types in the tumor and immune microenvironment (TIME)…
A pioneer in the metabolic solute carrier transporter (SLCT) space, a largely untapped target class, for hard-to-treat diseases such as cancer, autoimmunity, and inflammation…
Proceeds to support the development of small-molecule drugs that modulate the transport of metabolites for oncology and immunology indications Boston, January 26, 2021 – Nirogy Therapeutics Inc., a privately-held biotechnology …
Natick, Mass., September 25, 2020 – Nirogy Therapeutics Inc. today announced that it was awarded a $2M NIH/NCI SBIR grant to develop dual monocarboxylate transport inhibitors (dMCTi) for Triple Negative Breast …
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt mollitia animi, id est laborum et dolorum fuga. Et harum quidem rerum facilis est et expedita distinctio. Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum necessitatibus saepe eveniet ut et voluptates repudiandae sint et molestiae non recusandae. Itaque earum rerum hic tenetur a sapiente delectus, ut aut reiciendis voluptatibus maiores alias consequatur aut perferendis doloribus asperiores repellat